lenalidomide has been researched along with Central Nervous System Neoplasm in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 15 (78.95) | 24.3611 |
| 2020's | 3 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Baehring, JM; Kaulen, LD | 1 |
| Bagal, B; Bonda, A; Chatarjee, A; Dasgupta, A; Dey, S; Epari, S; Goda, J; Gupta, T; Jain, H; Kakoti, S; Khanna, N; Laskar, S; Nayak, L; Sarma, R; Sengar, M | 1 |
| Chen, H; Duan, X; Lin, D; Liu, H; Miao, C; Nie, T; Wu, J; Zhang, X; Zheng, Y; Zhong, W | 1 |
| Fujimoto, A; Hiramoto, N; Ishikawa, T; Matsushita, A | 1 |
| Bai, JF; Feng, R; Han, HX; Li, JT; Liu, H; Wang, T; Zhang, CL | 1 |
| Gupta, NK; Mannis, GN; Rubenstein, JL; Wang, CC; Yu, JJ | 1 |
| Ayed, AO; Cavallo, F; Chiappella, A; Congiu, AG; Gaidano, G; Laplant, BR; Macon, WR; Musuraca, G; Nowakowski, GS; Pederson, L; Re, A; Spina, M; Vitolo, U; Witzig, T | 1 |
| Chen, L; Chen, N; Choi, K; Damato, B; Formaker, P; Fraser, EJ; Gangoiti, J; Geng, H; Hwang, J; Killea, P; Kurhanewicz, J; Li, J; Lowell, C; Munster, PN; Rubenstein, JL; Sharma, J; Sneed, PK; Treseler, P; Ventura, J; Wang, X | 1 |
| Illerhaus, G; Kasenda, B; Schorb, E | 1 |
| Craft, M; Crispin, P; Koo, RM; Lalloo, S | 1 |
| Batchelor, TT; Grommes, C; Nayak, L; Tun, HW | 1 |
| Beauchesne, P; Cassoux, N; Chevrier, M; Chinot, O; Choquet, S; Ghesquieres, H; Gressin, R; Gyan, E; Hoang-Xuan, K; Houillier, C; Laadhari, M; Le Garff-Tavernier, M; Moluçon-Chabrot, C; Morschhauser, F; Nicolas-Virelizier, E; Savignoni, A; Schmitt, A; Soumelis, V; Soussain, C; Touitou, V; Turbiez, I | 1 |
| Geng, H; Hwang, J; Mannis, G; Rubenstein, JL; Vu, K | 1 |
| Madabhavi, IV; Modi, MG; Revannasiddaiah, S; Sarkar, MS | 1 |
| Choquet, S; Hoang-Xuan, K; Houillier, C; Martin-Duverneuil, N; Mokhtari, K; Navarro, S; Soussain, C; Touitou, V | 1 |
| Blaney, SM; Boyett, JM; Fangusaro, J; Goldman, S; Jakacki, R; Kun, LE; Macdonald, T; Packer, R; Pollack, IF; Schaiquevich, P; Stewart, CF; Wallace, D; Warren, KE | 1 |
| Cox, MC; Lionetto, L; Mannino, G; Naso, V; Simmaco, M; Spiriti, MA | 1 |
| Carney, DA; Gangatharan, SA; Harrison, SJ; Januszewicz, EH; Prince, HM; Ritchie, DS; Wolf, MM | 1 |
| Albert, PS; Duic, JP; Figg, WD; Fine, HA; Kim, L; Ma, H; Royce, C; Tohnya, T; Zhang, W | 1 |
3 review(s) available for lenalidomide and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Treatment Options for Recurrent Primary CNS Lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Central Nervous System Neoplasms; Cranial Irradiation; Cyclophosphamide; Cytarabine; Humans; Immune Checkpoint Inhibitors; Lenalidomide; Lymphoma, Non-Hodgkin; Methotrexate; Nivolumab; Pemetrexed; Procarbazine; Prospective Studies; Receptors, Chimeric Antigen; Retrospective Studies; Rituximab; Temozolomide; Thiotepa; Vincristine | 2022 |
Novel agents for primary central nervous system lymphoma: evidence and perspectives.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Nivolumab; Piperidines; Pyrazoles; Pyrimidines; Recurrence | 2018 |
Introduction of novel agents in the treatment of primary CNS lymphoma.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aminopyridines; Antineoplastic Agents, Immunological; Burkitt Lymphoma; Central Nervous System Neoplasms; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rituximab; Salvage Therapy; Thalidomide; Toll-Like Receptors; TOR Serine-Threonine Kinases; Tumor Escape | 2019 |
6 trial(s) available for lenalidomide and Central Nervous System Neoplasm
| Article | Year |
|---|---|
CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Prednisone; Rituximab; Treatment Outcome; Vincristine | 2018 |
Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.
Topics: Aged; Central Nervous System Neoplasms; Disease-Free Survival; Female; Humans; Lenalidomide; Lymphoma; Maintenance Chemotherapy; Male; Middle Aged; Recurrence; Rituximab; Survival Rate | 2018 |
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Drug Administration Schedule; Female; Follow-Up Studies; France; Humans; Intention to Treat Analysis; Intraocular Lymphoma; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Proof of Concept Study; Prospective Studies; Remission Induction; Rituximab | 2019 |
Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Area Under Curve; Central Nervous System Neoplasms; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Recurrence; Thalidomide; Young Adult | 2011 |
Emergence of central nervous system myeloma in the era of novel agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Central Nervous System Neoplasms; Combined Modality Therapy; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Prognosis; Pyrazines; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2012 |
A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Neoplasm Recurrence, Local; Thalidomide | 2007 |
10 other study(ies) available for lenalidomide and Central Nervous System Neoplasm
| Article | Year |
|---|---|
Lenalidomide following whole-brain radiotherapy in patients with primary central nervous system lymphoma ineligible for intensive systemic therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Central Nervous System; Central Nervous System Neoplasms; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Rituximab | 2023 |
Cerebral delivery of redox-responsive lenalidomide prodrug plus methotrexate for primary central nerve system lymphoma combination therapy.
Topics: Brain Neoplasms; Central Nervous System Neoplasms; Humans; Lenalidomide; Lymphoma; Methotrexate; Oxidation-Reduction; Prodrugs | 2023 |
[Successful treatment with lenalidomide-containing regimen of plasma cell leukemia accompanied by meningeal involvement].
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Female; Humans; Lenalidomide; Leukemia, Plasma Cell; Middle Aged; Prognosis | 2019 |
[Lenalidomide, rituximab and dexamethasone for the treatment of recurrent/refractory or elderly newly diagnosed patients with primary central nervous system lymphoma: 5 cases report and literature review].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Dexamethasone; Humans; Lenalidomide; Lymphoma; Neoplasm Recurrence, Local; Rituximab; Treatment Outcome | 2019 |
Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Central Nervous System Neoplasms; Drug Resistance, Viral; Female; Humans; Lenalidomide; Lymphoma, AIDS-Related; Thalidomide; Treatment Outcome | 2017 |
Successful treatment of central nervous system myeloma manifesting as cauda equina nodules with intrathecal chemotherapy, lenalidomide and dexamethasone.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Cauda Equina; Central Nervous System Neoplasms; Dexamethasone; Humans; Injections, Spinal; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Treatment Outcome | 2018 |
Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Induction Chemotherapy; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Treatment Outcome | 2019 |
Sanctuary site central nervous system relapse-refractory DLBCL responding to nivolumab and lenalidomide.
Topics: Adult; Brain Edema; Central Nervous System Neoplasms; Drug Administration Schedule; Humans; Injections, Spinal; Intensive Care Units; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Nivolumab; Treatment Outcome | 2019 |
Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma.
Topics: Aged; Angiogenesis Inhibitors; Central Nervous System Neoplasms; Female; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Thalidomide | 2015 |
Lenalidomide for aggressive B-cell lymphoma involving the central nervous system?
Topics: Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Chromatography, Liquid; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Magnetic Resonance Imaging; Male; Orbit; Tandem Mass Spectrometry; Thalidomide | 2011 |